

STATE OF CONNECTICUT

DEPARTMENT OF PUBLIC HEALTH



Raul Pino, M.D., M.P.H.
Commissioner

Dannel P. Malloy
Governor
Nancy Wyman
Lt. Governor

Environmental Health

EHS Circular Letter 2017-30

TO: Directors of Health
Chief Sanitarians
Regional Lead Treatment Centers
Physicians

FROM: Christine Hahn, Epidemiologist
Lead, Radon & Healthy Homes Program

DATE: August 28, 2017

SUBJECT: High levels of lead found in Balguti Kesaria Ayurvedic Medicine

On August 4, 2017 the U.S. Food and Drug Administration (FDA) issued a warning for “Balguti Kesaria (or Kesaria Balguti) Ayurvedic Medicine” due to the risk of lead poisoning.

This product is sold online and manufactured by multiple companies, including Kesari Ayurvedic Pharmacy in India. “Balguti Kesaria Ayurvedic Medicine” is used with infants and children for a variety of conditions including rickets, cough and cold, worms and pain relief for baby teething. To date, FDA has received one adverse event report of high levels of lead and developmental delays in a child.

The warning can be found on the FDA website at:

<https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm570257.htm>

FDA would like physicians to report any adverse events potentially related to “Balguti Kesaria Ayurvedic Medicine” to FDA’s MedWatch Adverse Event Reporting program:

- Download and complete the MedWatch Online Voluntary Reporting Form found at <https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home>
- Submit the form via fax at 1-800-FDA-0178

Please direct all questions to the Connecticut Department of Public Health Lead, Radon & Healthy Homes Program at 860-509-7299.

cc: Suzanne Blancaflor, M.P.H., M.S., Chief, Environmental Health Section



Phone: (860) 509-7299 • Fax: (860) 509-7295
410 Capitol Avenue, P.O. Box 340308
Hartford, Connecticut 06134-0308
www.ct.gov/dph

Affirmative Action/Equal Opportunity Employer



